companies must adopt a multipronged strategy. Investing in advanced biomanufacturing infrastructure is critical, as biosimilars require sophisticated production facilities and stringent quality controls. Companies must also focus on regulatory expertise, ensuring that their biosimilars meet global standards and can seamlessly navigate the complex approval pathways in the U. S., EU, and Japan. Additionally, forging strategic partnerships with global pharmaceutical giants can accelerate biosimilar development and market penetration.
Government support will also play a crucial role in helping Indian pharma companies seize this opportunity. Recognizing the potential of biosimilars, the Indian government has introduced policies such as the Production Linked Incentive( PLI) scheme, which incentivizes investments in biopharmaceutical manufacturing. Additionally, organizations like the Biotechnology Industry Research Assistance Council( BIRAC) are supporting biotech startups and R & D initiatives, further strengthening India’ s position in the biosimilars market.
Set To Grow By Leaps And Bounds
In 2024, the Indian biosimilars industry is experiencing robust
S. No. Key Indian Biosimilars Players
1 Biocon Biologics
2 Dr. Reddy ' s Laboratories
3 Intas Pharmaceuticals
4 Reliance Life Sciences
5 Zydus Cadilla
6 Lupin
7 Cipla
8 Panacea Biotec
9 Enzene Biosciences
10 Aurobindo Pharma
11 Glenmark Pharmaceuticals
12 Hetero Drugs
13 Biological E. Limited
14 Wockhardt
15 Alkem Laboratories
16 Torrent Pharmaceuticals
17 Encume Pharmaceuticals
18 Strides Pharma Science
19 Bharat Serums & Vaccines Limited
20 Natco Pharma
BIOVOICENEWS. COM 19